🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/06/2021 23,21 23,62 22,36 23,51 +1,95% 5,43% 1.160.600
18/06/2021 23,62 24,06 22,84 23,06 -2,99% 5,17% 2.080.100
17/06/2021 23,89 24,34 23,29 23,77 -0,96% 4,42% 615.400
16/06/2021 24,49 24,95 23,59 24,00 -1,56% 5,55% 567.700
15/06/2021 24,57 25,17 23,92 24,38 -0,69% 5,09% 482.400
14/06/2021 25,04 25,23 24,45 24,55 -1,37% 3,10% 461.800
11/06/2021 25,04 25,45 24,74 24,89 +0,04% 2,86% 280.200
10/06/2021 24,61 25,08 24,20 24,88 +1,88% 3,58% 365.900
09/06/2021 25,04 25,58 24,13 24,42 -1,37% 5,77% 417.400
08/06/2021 25,47 25,92 24,25 24,76 -2,29% 6,56% 570.000
07/06/2021 25,12 25,54 24,83 25,34 +1,16% 2,83% 724.700
04/06/2021 24,91 25,52 24,80 25,05 +1,05% 2,89% 311.000
03/06/2021 24,57 25,01 24,13 24,79 +0,94% 3,58% 277.900
02/06/2021 24,64 25,44 24,20 24,56 -0,12% 5,03% 469.100
01/06/2021 24,62 25,04 24,20 24,59 -0,93% 3,41% 710.400
28/05/2021 25,00 25,37 24,60 24,82 -0,28% 3,08% 405.000
27/05/2021 24,44 25,20 24,06 24,89 +1,59% 4,66% 851.600
26/05/2021 24,47 24,75 24,14 24,50 +1,53% 2,49% 610.700
25/05/2021 24,60 24,92 23,58 24,13 -1,71% 5,45% 947.200
24/05/2021 25,36 25,70 24,41 24,55 -2,54% 5,09% 275.500
21/05/2021 26,26 26,26 25,14 25,19 -2,48% 4,27% 439.800
20/05/2021 26,10 26,60 25,41 25,83 -0,50% 4,56% 475.600
19/05/2021 27,15 27,15 25,58 25,96 -5,19% 5,78% 769.000
18/05/2021 28,12 28,37 27,23 27,38 -2,11% 4,05% 465.300
17/05/2021 28,49 29,00 27,81 27,97 -1,93% 4,18% 299.300
14/05/2021 28,03 29,19 27,87 28,52 +3,15% 4,71% 407.500
13/05/2021 29,49 29,78 27,36 27,65 -5,15% 8,21% 472.400
12/05/2021 28,24 30,39 28,24 29,15 +1,46% 7,61% 459.900
11/05/2021 28,27 29,50 28,17 28,73 -0,45% 4,70% 935.900
10/05/2021 30,07 30,46 28,62 28,86 -5,22% 6,12% 567.900